Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT07148843
Phase
PHASE2/PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Alcohol Use Disorder (AUD)
  • Craving
  • Withdrawal From Addictive Substance; Detoxification

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Cannabidiol (CBD) — DRUG
    Cannabidiol
  • Placebo — DRUG
    placebo

Study Details

Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of these are common symptoms of alcohol withdrawal. This randomized placebo-controlled clinical trial will evaluate the potential of CBD to improve alcohol withdrawal symptoms and reduce craving during acute abstinence among individuals with moderate-to-severe AUD. Adult participants with moderate-to-severe AUD will be admitted to an inpatient research unit at the Johns Hopkins Hospital for a 5-day, 4-night stay that includes alcohol abstinence with management of their alcohol withdrawal. In addition to standard care, participants will receive CBD or placebo (no CBD), complete assessments of withdrawal, sleep quality and provide breath and blood samples.

Key Dates

Start date
Aug 1, 2026
Status verified
Apr 2026
Primary completion
Oct 31, 2030
Completion
Oct 31, 2030

Study Design

Enrollment
105 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 10 mg/kg CBD
    low dose CBD
  • Active Comparator: 20 mg/kg CBD
    high dose CBD
  • Placebo Comparator: placebo
    Placebo (no CBD)

Primary Outcome Measure

Peak score on the Alcohol Withdrawal Symptom Checklist (AWSC) [ Time Frame: Four times daily during inpatient stay (4 nights) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Behavioral Pharmacology Research UnitBaltimoreMaryland21224
David Wolinsky, MD
[email protected]
410-550-2253
Elise Weerts, PhD
[email protected]
410-550-2781

Find similar trials in Baltimore, MD

By research site
Behavioral Pharmacology Research Unit· Baltimore, MD

Related Studies